How Pierce was paid
$225,036 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Other | Total |
|---|---|---|---|---|---|
| Frederick E. PierceChief Executive Officer | $29,607 | — | $195,429 | — | $225,036 |
| Mark J. RosenblumExecutive Vice President, Finance, Chief Financial Officer and Former Acting Chief Executive Officer | $330,000 | $225,000 | — | $14,000 | $569,000 |
| David J. ArthurFormer President and Chief Executive Officer | $68,300 | — | — | $37,930 | $106,229 |
| Barbara Hibner, Ph.D.Chief Scientific Officer | $29,607 | — | $195,429 | — | $225,036 |
| Peter MarschelChief Business Officer | $29,607 | — | $195,429 | — | $225,081 |
What changed and why
- 35%35% was the target annual bonus percentage for Rosenblum, Pierce, Hibner and Marschel.
- $225K$225,000 was Rosenblum’s one-time transaction bonus for the Merger closing.
- November 12, 2025 marked Pierce, Hibner and Marschel’s commencement as Company executive officers.
- No awards were granted to named executive officers in 2025 by the Company.
- Legacy Decoy options held by Pierce, Hibner and Marschel were assumed and converted at the Merger closing.
- $500K$500,000 of Arthur’s 2024 other compensation was severance under his Separation and Release Agreement.
Other Decoy Therapeutics proxy statements
- 2025 proxy statement
David J. Arthur paid $734,450 (+35% on the year).
Filed Nov 07, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.